Sarepta Signs a License Agreement with Stride Bio to Develop In vivo AAV-Based Gene Therapies

 Sarepta Signs a License Agreement with Stride Bio to Develop In vivo AAV-Based Gene Therapies

Sarepta Signs a License Agreement with Stride Bio to Develop In vivo AAV-Based Gene Therapies

Shots:

  • The companies collaborated to develop in vivo AAV-based therapies for up to eight central nervous system and neuromuscular targets. StrideBio will be responsible for research, development and manufacturing of the first four CNS targets which include MECP2 (Rett syndrome), SCN1A (Dravet syndrome), UBE3A (Angelman syndrome), and NPC1 (Niemann-Pick)
  • Stride Bio to receive $48M upfront in cash & Sarepta’s shares, development, regulatory & commercial milestones for 4 programs and royalties on sales of products developed via collaboration. Sarepta to get an exclusive license on selected targets leveraging StrideBio’s capsid technology
  • Additionally, Sarepta to get an exclusive option to expand the collaboration for up to additional four targets in exchange of ~ $42.5M with milestones and an option to obtain co-development and co-commercial rights for one target

Click here to­ read full press release/ article | Ref: Sarepta | Image:  Bloomberg

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post